Volume | 854,598 |
|
|||||
News | - | ||||||
Day High | 1.57 | Low High |
|||||
Day Low | 1.45 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Atossa Therapeutics Inc | ATOS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.48 | 1.45 | 1.57 | 1.52 | 1.50 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
4,246 | 854,598 | $ 1.51 | $ 1,287,935 | - | 0.5901 - 2.31 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:09:37 | 2 | $ 1.54 | USD |
Atossa Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
191.72M | 125.30M | - | 0 | -30.09M | -0.24 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Atossa Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATOS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.31 | 1.595 | 1.24 | 1.45 | 1,621,447 | 0.23 | 17.56% |
1 Month | 1.85 | 2.31 | 1.24 | 1.75 | 2,794,036 | -0.31 | -16.76% |
3 Months | 0.85 | 2.31 | 0.8279 | 1.59 | 1,764,835 | 0.69 | 81.18% |
6 Months | 0.66 | 2.31 | 0.62 | 1.44 | 1,021,495 | 0.88 | 133.33% |
1 Year | 0.67 | 2.31 | 0.5901 | 1.25 | 851,313 | 0.87 | 129.85% |
3 Years | 1.77 | 9.80 | 0.50 | 3.76 | 3,327,796 | -0.23 | -12.99% |
5 Years | 3.48 | 9.80 | 0.50 | 3.18 | 3,500,469 | -1.94 | -55.75% |
Atossa Therapeutics Description
Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use. |